Lung Cancer Vaccine Therapy

• Sugiura Miki

  Department of Immunotherapeutics (Medinet), The University of Tokyo Hospital Department of Cardiothoracic Surgery, The University of Tokyo Hospital

• Yoshida Yukihiro

  Department of Immunotherapeutics (Medinet), The University of Tokyo Hospital Department of Cardiothoracic Surgery, The University of Tokyo Hospital

• Nakajima Jun

  Department of Cardiothoracic Surgery, The University of Tokyo Hospital

• Kakimi Kazuhiro

  Department of Immunotherapeutics (Medinet), The University of Tokyo Hospital

• Wada Hiromi

  Wada Clinic Osaka

Bibliographic Information

Other Title

• 原発性肺癌に対するがんワクチン治療

Abstract

Lung cancer is the leading cause of cancer death in Japan and still requires more effective treatments. The potential of cancer vaccines is promising, although there are no satisfactory protocols available for lung cancer at present. However, encouraging evidence of clinical benefits from cancer vaccines is beginning to accumulate in several lung cancer trials. Here, we review recent advances in lung cancer vaccine trials, especially 5 phase III cancer vaccine trials including MAGE-A3, EGF, MUC-1, Belagenpumatucel-L, and MVA-MUC1-IL-2. In addition, we will focus on several phase I or II studies that take into account new strategies to overcome immune suppressive microenvironment and suggest future directions of lung cancer vaccines.<br>

Journal

• Haigan

  Haigan 49 (6), 823-830, 2009

  The Japan Lung Cancer Society

Keywords

• Cancer vaccine
• Immunotherapy
• MAGE-A3
• MUC-1

Details

• CRID: 1390001204682861312
• NII Article ID: 130000123020
• DOI: 10.2482/haigan.49.823
• ISSN: 13489992
• ISSN: 03869628
• Web Site: http://www.jstage.jst.go.jp/article/haigan/49/6/49_6_823/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2010053915
• Text Lang: ja
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed